Related Experiment Video

Updated: Feb 20, 2026

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.9K

BET inhibitors as novel therapeutic agents in breast cancer

Alberto Ocaña1, Cristina Nieto-Jiménez1, Atanasio Pandiella2

  • 1Unidad de Investigación Traslacional, Hospital Universitario de Albacete, Universidad de Castilla La Mancha, Albacete, Spain.

Oncotarget
|October 21, 2017
PubMed

Insights

Bromodomain and extra-terminal (BET) inhibitors show promise in treating breast cancer by halting tumor cell growth. This review explores their effectiveness, especially in triple-negative breast cancer, and future clinical applications.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Malignant cells exploit oncogenic and non-oncogenic vulnerabilities.
  • Epigenomic targeting can modulate cellular functions crucial for cancer development.
  • Bromodomain and extra-terminal (BET) inhibitors target transcription machinery by recognizing acetylated histones.

Purpose of the Study:

  • To review the current knowledge on BET inhibitors in breast cancer treatment.
  • To discuss the antiproliferative effects of BET inhibitors across various breast cancer subtypes.
  • To explore therapeutic combinations, resistance mechanisms, and future clinical development of BET inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies on BET inhibitors in breast cancer.
  • Analysis of data on the efficacy of BET inhibitors in different breast cancer subtypes, including triple-negative breast cancer.
  • Examination of studies investigating combinations of BET inhibitors with other therapies and mechanisms of resistance.

Main Results:

  • BET inhibitors demonstrate antiproliferative effects in several breast cancer subtypes.
  • Efficacy is noted in triple-negative breast cancer and in combination with cell signaling inhibitors.
  • Potential therapeutic combinations and mechanisms of resistance have been identified.

Conclusions:

  • BET inhibitors represent a promising therapeutic strategy for breast cancer.
  • Further research into combinations and resistance mechanisms is crucial for clinical development.
  • Future clinical trials are warranted to establish the role of BET inhibitors in breast cancer treatment.
Keywords:
BET inhibitorsbreast cancernovel targets

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
531